BioSpace News Archive

MYOS CORP, a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, announced that it has entered a partnership with Patterson Veterinary, one of North America’s leading animal health distribution companies.

Nikon Instruments Inc., innovator of advanced microscope systems, is pleased to announce the inauguration of the Center of Excellence located at the Lunenfeld-Tanenbaum Research Institute of Sinai Health in Toronto.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the first patient has been treated in its Phase 1b Amyloid Light Chain (AL) Amyloidosis study of STI-6129, an ADC which uses STI-5171, a fully human monoclonal antibody (mAb) from Sorrento’s G-MAB™ library.

Boston Children’s Hospital announced the launch of the Digital Wellness Lab, a first-of-its-kind research and innovation incubator bringing together science-based solutions and information about the effects of digital technology on our brains, bodies, and behaviors.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the fourth quarter and full year 2020 and provided a corporate and clinical update.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Joshua Reed has been appointed to Scholar Rock’s Board of Directors as an independent director.

SenesTech, Inc., a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, announced the conclusion of agricultural deployments of ContraPest® with demonstrated, sustained success in reducing rat populations and improving operating economies in poultry settings.

Company continuing to advance its U.S. pivotal PURSUIT trial in stress urinary incontinence Conference call to be hosted by Company at 5:00 PM ET today

Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months and full year ending December 31, 2020, and highlighted its key corporate objectives for 2021 and early 2022.

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests